The U.S. Food and Drug Administration issued a new draft guidance to industry for developing plans to enroll more participants from underrepresented racial and ethnic populations in the U.S. into clinical trials – expanding on the agency’s previous guidances for industry to improve clinical trial diversity.
The Covid-19 epidemic highlighted the disproportionate way the virus impacted minority communities across the U.S., increasing the calls for racial and ethnic diversity in clinical studies. While there has been a more significant push, a recent Pfizer clinical trials diversity report shows there is still a wide gap that needs to be bridged.
Abbott became the first anchor sponsor of the American Diabetes Association’s Health Equity Now platform to address health disparities for people with diabetes.
Nearly 300,000 more people have died in the United States in 2020 during the coronavirus pandemic than expected based on historical trends, with about two-thirds of the deaths due to Covid-19 illnesses, according to a report.